This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
However, Section 3(d) has been an issue for the big pharmaceutical companies, as an obstruction to get secondary patents on trivial variations because it blocks patents from becoming “evergreen” and gives opportunity to generic pharmaceutical firms to produce biosimilar drugs and sell them at a much lower price.
PatentApplication 15/131,442 (the “’442 Patent”) with claims directed to a method of increasing prostacyclin release in systemic blood vessels of a human to improve vasodilation and reduce hypertension. Background John L. Couvaras filed U.S. to note that “[a]rguments raised only in footnotes [] are waived.” Otsuka Pharm.
In 2014, UCB sued Actavis for infringement of the Muller patents. UCB prevailed in the lawsuit, and was awarded an injunction against Actavis until March 2021, when one of the Muller patents expires. In 2018, UCB filed a new patentapplication (the “’589 patent”, priority date 2009) covering a reformulation of Neupro.
Highlights of the Week Cheroots to Cheers or Bringing IP Conversations to Wider Audiences: A SpicyIP Initiative for Vernacular Dissemination ‘De-code Indian IntellectualPropertyLaw’ – For who? The deadline to file the comments is February 28.
Highlights of the Week Cheroots to Cheers or Bringing IP Conversations to Wider Audiences: A SpicyIP Initiative for Vernacular Dissemination ‘De-code Indian IntellectualPropertyLaw’ – For who? The deadline to file the comments is February 28.
Also, the Government has recently made an Amendment to the Patent Rule i.e. Indian Patent (Amendment) Rules, 2024 which aims to rationalize the patentapplication process and reduce the burden of the compilation and accelerate actions. Trademarks and Registered Trademarks, Control of Corp Diseases, 2012.
Some people may have anticipated that, in raising the standard of inventive step and introducing stricter requirements for enablement and support of claims, the RtB reforms would result in fewer applications being accepted. I was not one of those people, and I expect that neither were most other patent attorneys.
Claim Amendments u/s 59(1): Confusingly Evolving Landscape in India- Part I Amit Tailor Image from here The Delhi High Court (the “DHC”) has become the epicenter for IntellectualProperty litigation (and adjudication) in India. One such aspect of the Patent Act is ‘allowable claim amendments u/s 59(1) ’.
Hrdy, Professor of IntellectualPropertyLaw at University of Akron School of Law, and Daniel H. Brean, Senior In-House IntellectualProperty Counsel, Respiratory Care, Philips. Are inventions described in works of science fiction patentable? 709 (2012). Guest post by Camilla A.
SpicyIP Tidbits: Clarification on Jurisdiction of High Courts after the Tribunals Reform Act 2021, and Need for Reasoned Orders for Rejecting PatentApplications. Then we discussed the Bombay High Court’s decision to rebuke the Patent Office for dismissing a patentapplication without providing sufficient reasons for the same.
It states that these tools and datasets have been made freely available to third parties in conformity with intellectualpropertylaws. It further notes that India ranks 8 th in AI patents, and 4 th in terms of AI scholarly papers.
Highlights of the Week Announcing the 2024 Shamnad Basheer Essay Competition on IntellectualPropertyLaw Prof (Dr.) Shamnad Basheer’s 48th birth anniversary today, we are excited to announce the 2024 Shamnad Basheer Essay Competition on IP Law! This and much more in last week’s SpicyIP Weekly Review.
Sara’s IP litigation experience includes both patent litigation and trade secret misappropriation litigation, which often also include various associated breach of contract and business torts. from the University of Georgia School of Law and was the senior notes editor of the Journal of IntellectualPropertyLaw.
We organize all of the trending information in your field so you don't have to. Join 9,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content